Recovery and quality of life after limb-sparing surgery for soft tissue sarcoma
Official title: Body Image, Health-related Quality of Life, and Function After Soft Tissue Sarcoma Resection
Run by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · NCT06962072 · Data updated 2026-11-12
This project will see how body image, quality of life, walking ability, and joint and muscle function are in people who had limb-sparing surgery for localized soft tissue sarcoma of an arm or leg.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 150 (estimated) |
| Sponsor | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) Academic / other |
| Locations | 1 site (Amsterdam) |
| Status | Recruiting |
| Started | April 24, 2025 |
| Main results expected | January 1, 2028 |
| Study ends | January 1, 2028 |
| Registry record updated | December 19, 2025 |
| Trial ID | NCT06962072 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults who had primary non-metastatic extremity soft tissue sarcoma removed at Amsterdam UMC between 2010 and 2021 and who can attend one or two on-site visits at the Amsterdam UMC (AMC) are the intended participants.
✕Probably not a fit
People whose cancer was not treated at Amsterdam UMC, who have active metastatic disease, or who cannot complete the required walking tests are not eligible or will not contribute to some functional measures and are therefore less likely to benefit from the study's findings.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a cross-sectional follow-up of patients who underwent surgical resection for non-metastatic extremity soft tissue sarcoma at Amsterdam UMC between 2010 and 2021. Participants complete questionnaires, a physical exam, and objective tests including 3D gait analysis, a 6-minute walk test with gas analysis, muscle strength testing, and MRI comparisons to measure muscle-volume change. The study links these functional and structural measures to patient-reported body image, health-related quality of life, activity limitations, and pain. Researchers will also compare outcomes between patients treated with and without radiotherapy and explore factors such as ethnicity that may influence recovery.
Why it matters
Potential benefit: If successful, the findings could identify common functional deficits and body-image concerns and guide more personalized rehabilitation and follow-up care to improve long-term quality of life.
How similar studies have gone: Prior observational studies have shown lasting functional and body-image issues after limb-sparing resections, but combining detailed 3D gait analysis, gas analysis during a 6-minute walk, and MRI-based muscle-volume comparison is less common.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Treated with surgical resection for primary non-metastatic extremity STS at the Amsterdam UMC between 2010-2021. * Being able to visit the Amsterdam UMC, location AMC once or twice. * Pregnant patients must agree to be scheduled 5 months after their pregnancy ends. Exclusion Criteria: * Patients who cannot maintain 6 minutes of walking will be excluded from the 6-minute walk test.
Where it's running
-
Amsterdam UMC
Amsterdam, Netherlands Recruiting
Study contacts
- Study coordinator: Floortje G.M. Verspoor, MD/PhD
- Email: f.g.verspoor@amsterdamumc.nl
- Phone: +310205669111
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
68Ga-HX01 PET/CT Imaging in Soft Tissue Sarcoma patients
This study tests whether a 68Ga-HX01 injection can help PET/CT imaging better characterize soft tissue sarcoma in adults who have exhausted standard treatments or have no good options.
-
Zemetostat plus Anlotinib for SWI/SNF-deficient Head and Neck Soft Tissue Sarcoma
This trial tests whether zemetostat plus anlotinib can help people with recurrent or metastatic head-and-neck soft tissue sarcoma that has SWI/SNF complex deficiency after standard therapy fails.
-
Entinostat for pediatric soft tissue sarcoma with PAX abnormalities
This study tests entinostat, alone or with chemotherapy, in children whose soft tissue sarcomas have PAX-family gene abnormalities to see if it can help shrink tumors or slow progression.
-
Methionine-Reduced Diet in Solid Tumors (early-phase)
A small pilot study will test whether a methionine-reduced diet can change blood levels in adults with various solid tumors who are receiving standard cancer therapy.
-
Preoperative Immunonutrition for bone and soft tissue sarcoma patients
This study tests whether a short course of an oral nutrition supplement before surgery can help patients with bone or soft tissue sarcomas recover better after major tumor-related surgery.
-
Adaptive Proton Therapy for Pediatric Solid Tumors and Hodgkin Lymphoma
This study tests a regular imaging approach to see if proton therapy plans for children with solid tumors or Hodgkin lymphoma should be updated during treatment.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.